Efficacy and safety of Lemborexant in treating adult patients with insomnia in China: a single-center, retrospective observational study.

ABSTRACT:

Background

Except for one case report, there has been no published study of Lemborexant treatment for patients with insomnia in China. This study investigated efficacy and safety of Lemborexant in treating Chinese patients with insomnia.

Methods

In this single-center, retrospective observational study, adult patients diagnosed with insomnia with an Insomnia Severity Index (ISI) score of ≥8 who were prescribed Lemborexant at Guangzhou United Family Hospital from January 2023 to July 2024 and who had ≥2 follow-up ISI assessment(s) were included. The primary outcome was change in the ISI total score from baseline after 4 weeks of Lemborexant treatment. Treatment-emergent adverse events (TEAEs) were collected.

Results

Forty patients with a mean baseline ISI score of 17.0 

SUBMITTER: Jian W 

PROVIDER: S-EPMC11949819 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature